Great Point Partners’s Sarepta Therapeutics SRPT Stock Holding History

Great Point Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-80,000	Closed	-$7.71M	–	42
2023 Q4	$7.71M	Sell	80,000 -85,200	-52%	-$8.17M	1.31%	26
2023 Q3	$20M	Buy	165,200 +41,600	+34%	+$4.7M	3.65%	9
2023 Q2	$14.2M	Buy	+123,600	New	+$15.9M	2.77%	16
2023 Q1	–	Sell	-73,000	Closed	-$9.46M	–	51
2022 Q4	$9.46M	Buy	+73,000	New	+$8.46M	1.85%	23
2022 Q3	–	Sell	-193,900	Closed	-$14.5M	–	47
2022 Q2	$14.5M	Buy	+193,900	New	+$14.3M	3.49%	12
2022 Q1	–	Sell	-145,405	Closed	-$13.1M	–	39
2021 Q4	$13.1M	Buy	+145,405	New	+$12.4M	2.91%	14
2017 Q4	–	Sell	-250,000	Closed	-$11.3M	–	45
2017 Q3	$11.3M	Buy	+250,000	New	+$9.99M	2.21%	19

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Great Point Partners's SRPT Position: Q1 2024 in Review

Great Point Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 80,000 shares — an estimated $7.71M sold.

Great Point Partners first reported a position in SRPT in Q3 2017 and held it in 7 quarters. The position peaked at $20M in Q3 2023. 415 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

Great Point Partners reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
Great Point Partners sold 80,000 Sarepta Therapeutics shares in Q1 2024, an estimated $7.71M.
Great Point Partners first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 7 quarters.
Great Point Partners's Sarepta Therapeutics position peaked at $20M in Q3 2023.
415 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Great Point Partners's 13F filing for Q1 2024, filed 15 May 2024.